Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BZAG sequential bendamustine followed by obinutuzumab, zanubrutinib, and venetoclax in relapsed/refractory CLL
2018-003270-27Phase 2Active
- Sponsor
- University of Cologne
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab, zanubrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Minimal residual disease negativity rate in peripheral blood. Started Dec 2019; status: active.
02
Drugs
bendamustineobinutuzumabzanubrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-003270-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003270-27.